Potential therapeutic effects and applications of Eucommiae Folium in secondary hypertension

Li, Mengyuan; Zheng, Yuankai; Deng, Sha; Yu, Tian; Ma, Yucong; Ge, Jiaming; Li, Jiarong; Li, Xiankuan; Ma, Lin

doi:10.1016/j.jpha.2021.10.004

Cited by 5 publications

(6 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to previous reports, isoquercitrin (14) shows similar pharmacological effects to Eucommiae Folium [34][35][36][37][38][39][40], especially the antihypertensive effect [41]. Although the old Q-marker chlorogenic acid also shows anti-hypertensive activity [3,42] (Table 1, entry 3), the molecular docking data indicated that the new Q-marker isoquercitrin played a more important role than chlorogenic acid for the structure advantage [41]. This means that adding a new Q-marker will enhance the pharmacological relevance of the Q-marker system [10].…”

Section: Resultsmentioning

confidence: 96%

“…The threshold value determination of the new Q-marker requires a specific project in the future. After all, pharmacopeia Q-marker update is a highly prudent work and quantitative determination is not the advantage of the UHPLC-Quadrupole-Orbitrap-MS technology used in the present study (3). The study is only an academic exploration regarding pharmacopeia Q-mark and has no legal authority.…”

mentioning

confidence: 92%

“…Eucommiae Folium (Figure 1) is the dried leaves of Eucommia ulmoides Oliver, a sole plant of the Eucommiaceae and kidney, as well as strengthen the tendon and bones [1]. Modern pharmacological investigations have indicated that Eucommiae Folium has various beneficial effects, especially the anti-hypertensive effect [3,4]. As a result, various anti-hypertensive functional foods or medicines have been consumed in China and Japan, including "Duzhongye tea" (in Chinese), "Tochu-cha" (in Japanese), and Eucommiae Folium granules [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ultra‐high‐performance liquid chromatography‐Quadrupole‐Exactive‐Orbitrap‐tandem mass spectrometry‐based putative identification for Eucommiae Folium (Duzhongye) and its quality‐marker candidate for pharmacopeia

Cai

et al. 2023

J of Separation Science

View full text Add to dashboard Cite

Eucommiae Folium (Duzhongye) is a traditional Chinese medicine with a long history of use in China. However, its quality-marker in Chinese Pharmacopoeia is poorly defined nowadays. The study, therefore, conducted an ultra-high-performance liquid chromatography coupled with hybrid quadrupole-orbitrap tandem mass spectrometry analysis to obtain accurate data. The obtained data were then compared with the authentic standards library using Xcalibur 4.1 software package and TraceFinder General Quan. Through the comparison, the study has putatively identified 26 bioactive compounds, which include 17 flavonoid derivatives (catechin, quercetin 3-gentiobioside, quercetin 3-O-β-D-glucose-7-O-β-D-gentiobioside, taxifolin, myricetin 3-O-galactoside, myricitrin, hyperoside, rutin, isoquercitrin, quercetin 3-O-β-xylopyranoside, quercitrin, isorhamnetin 3-O-β-D-glucoside, quercetin, kaempferol, S-eriodictyol, S-naringenin, and phloridzin), four caffeoylquinic acids (neochlorogenic acid, chlorogenic acid, isochlorogenic acid A, and isochlorogenic acid C), two alkaloids (vincamine and jervine), one lignan (pinoresinol), one xanthone (cowaxanthone B), and one steroid (cholesteryl acetate). Of these, flavonoid isoquercitrin is recommended as the new and additional pharmacopeia quality-marker candidate, which can not only overcome the unreliability of old quality-marker but also recognize the possible counterfeit.

show abstract

Section: Resultsmentioning

confidence: 96%

mentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ultra‐high‐performance liquid chromatography‐Quadrupole‐Exactive‐Orbitrap‐tandem mass spectrometry‐based putative identification for Eucommiae Folium (Duzhongye) and its quality‐marker candidate for pharmacopeia

Cai

et al. 2023

J of Separation Science

View full text Add to dashboard Cite

show abstract

“…Antihypertensive effects have been shown for other parts of DZ. DZ leaves are effective against secondary hypertension, such as renal hypertension and salt-sensitive hypertension, as well as hypertension caused by thoracic aortic endothelial dysfunction, high-fat diets, and oxidized low-density lipoprotein by regulating the Ras homolog family member A/Rho-associated protein kinase signaling and NO/soluble guanylate cyclase/cyclic guanosine monophosphate signaling pathways ( Li et al, 2022 ). In spontaneously hypertensive rats, the male flower extract of DZ exhibited antihypertensive effects by targeting the angiotensin-converting enzyme 2/angiotensin (1–7)/Mas signaling pathway ( Ding et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

“…Antihypertensive effects have been shown for other parts of DZ. DZ leaves are effective against secondary hypertension, such as renal hypertension and salt-sensitive hypertension, as well as hypertension (Li et al, 2022). In spontaneously hypertensive rats, the male flower extract of DZ exhibited antihypertensive effects by targeting the angiotensin-converting enzyme 2/angiotensin (1-7)/ Mas signaling pathway (Ding et al, 2020).…”

Section: Figurementioning

confidence: 99%

Quanduzhong capsules for the treatment of grade 1 hypertension patients with low-to-moderate risk: A multicenter, randomized, double-blind, placebo-controlled clinical trial

Tian

Duan

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Duzhong [DZ (Eucommia ulmoides Oliv.)] is regarded as a traditional Chinese medicine with a history dating back more than 2000 years. This herb is considered a nourishing herb in China and is commonly used as a tonic to strengthen muscles and bones, nourish the kidneys and liver, and soothe miscarriages. Moreover, there is evidence that DZ is capable of regulating blood pressure (BP), and several compounds isolated from DZ have been shown to have a BP-lowering effect. Quanduzhong capsules contain an extract of DZ [Eucommia ulmoides Oliv. (Eucommiaceae; Eucommiae cortex)] that is effective in treating hypertension. This multicenter, randomized, double-blind, placebo-controlled clinical trial sought to evaluate the clinical efficacy of Quanduzhong capsules in the treatment of low-to-moderate risk grade 1 hypertension patients.Materials and methods: A total of 60 patients from 3 centers with documented low-to-moderate risk grade 1 hypertension were randomly assigned in a 1:1 ratio to the test group or the control group. After a 1 week lead-in period using sham Quanduzhong capsules, all patients who met the entry criteria (29 cases in the test group and 29 cases in the control group) entered the 4 week test period. The test group took Quanduzhong capsules, and the control group continued to take sham Quanduzhong capsules. The primary endpoints [24-h mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) determined via 24-h ambulatory blood pressure monitoring (ABPM); office SBP and DBP] and secondary endpoints [mean arterial pressure; mean pulse; daytime mean SBP and DBP; nocturnal mean SBP and DBP; SBP and DBP load; area under the blood pressure (BP) curve; morning peak BP; early morning SBP and DBP; smoothness index of SBP and DBP; 24 h BP mean coefficient of variation (CV); percentage of patients with circadian restoration in ABPM; home BP; quality of life evaluated by WHO Quality of Life-BREF questionnaire; grading and quantitative evaluation of hypertension symptoms; values of plasmatic renin activity, angiotensin II, aldosterone, β-2 microglobulin and homocysteine] were assessed following the treatment. Drug-related adverse events and adverse drug reactions were also compared.Results: After a 4 week test period, a significant difference in the DBP CV between the two groups was observed (−2.49 ± 4.32 vs. 0.76 ± 4.3; p < .05). Moreover, the mean office SBP change was −7.62 ± 9.32 mmHg, and the mean DBP change was −4.66 ± 6.03 (p < .05). Among the three subjects with abnormal homocysteine levels in the test group, homocysteine levels decreased by 6.23 ± 9.15 μmol/L after treatment. No differences were observed between the two groups in any other indicators. After 4 weeks of treatment, there were no significant differences between the groups in terms of safety indicators (p > .05). No abnormal vital signs (except BP) or severe liver or renal function impairment were observed during the treatment periods; in addition, adverse events and drug reactions were mild.Conclusion: Treatment with Quanduzhong capsules reduced office SBP and DBP as well as DBP CV determined by 24-h ambulatory BP monitoring in patients with grade 1 hypertension at low-to-moderate risk.Clinical Trial Registration:https://www.chictr.org.cn/showproj.aspx?proj=32531, identifier ChiCTR1900021699.

show abstract

Identification of potential angiotensin-I-converting enzyme inhibitory components in celery seed using UHPLC-MS and molecular docking

Zheng

Liu

et al. 2023

Process Biochemistry

View full text Add to dashboard Cite

Potential therapeutic effects and applications of Eucommiae Folium in secondary hypertension

Cited by 5 publications

References 78 publications

Ultra‐high‐performance liquid chromatography‐Quadrupole‐Exactive‐Orbitrap‐tandem mass spectrometry‐based putative identification for Eucommiae Folium (Duzhongye) and its quality‐marker candidate for pharmacopeia

Ultra‐high‐performance liquid chromatography‐Quadrupole‐Exactive‐Orbitrap‐tandem mass spectrometry‐based putative identification for Eucommiae Folium (Duzhongye) and its quality‐marker candidate for pharmacopeia

Quanduzhong capsules for the treatment of grade 1 hypertension patients with low-to-moderate risk: A multicenter, randomized, double-blind, placebo-controlled clinical trial

Identification of potential angiotensin-I-converting enzyme inhibitory components in celery seed using UHPLC-MS and molecular docking

Contact Info

Product

Resources

About